Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial.

Mavoko, Hypolite Muhindo; Nabasumba, Carolyn; da Luz, Raquel Inocêncio; Tinto, Halidou; D'Alessandro, Umberto; Kambugu, Andrew; Baraka, Vito; Rosanas-Urgell, Anna; Lutumba, Pascal; Van Geertruyden, Jean-Pierre; (2016) Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. The Lancet Global health, 5 (1). e60-e68. ISSN 2214-109X DOI: https://doi.org/10.1016/S2214-109X(16)30236-4

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S2214-109X(16)30236-4

Abstract

Share

Download

Filename: Efficacy and safety of re-treatment_GOLD VoR.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar